ReviewBJC reports2023
Direct administration of human leucocyte antigen (dHLA) molecules into tumour sites: proposal for a new immunotherapy for cancer.
Review in BJC reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Solid tumor rejection using personalized incompatible human leukocyte antigen (HLA) and blood group ABH antigens.Exploration of medicine · 2025Article
- Article
- Nine Human Leukocyte Antigen (HLA) Class I Alleles are Omnipotent Against 11 Antigens Expressed in Melanoma Tumors.Cancer informatics · 2024Article
- Association between brain cancer immunogenetic profile and in silico immunogenicities of 11 viruses.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural elimination of cancer cells is mediated by human leucocyte antigen (HLA) Class I and II molecules [1] that bind to tumour protein fragments, move to the tumour cell surface and engage CD8+ lymphocytes for killing the tumour cell (HLA Class I) and CD4+ lymphocytes for antibody production against the tumour cell (HLA Class II). HLA Class I molecules are present in all nucleated cells, whereas Class II molecules are present only in antigen presenting cells, such as macrophages. These defence mechanisms are suppressed by tumour cells; this tumour-induced immunosuppression is partly reversed by immune checkpoint inhibitors (ICI), thus allowing the HLA-based tumour elimination to be active again; indeed, the success of ICI therapy partly depends on the HLA makeup of the recipient [2, 3]. Here, we propose a novel cancer immunotherapy consisting of administering the mRNA blueprints for the synthesis of specific HLA Class I molecules with high binding affinity and high immunogenicity to a tumour's neoantigens. This should maximise the effectiveness of HLA-mediated tumour elimination.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.